S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
Log in
NYSE:NVTA

InVitae Stock Forecast, Price & News

$48.39
+1.36 (+2.89 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$46.98
Now: $48.39
$50.42
50-Day Range
$30.23
MA: $40.69
$53.31
52-Week Range
$7.41
Now: $48.39
$55.38
Volume2.52 million shs
Average Volume3.10 million shs
Market Capitalization$6.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.03
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Read More
InVitae logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone415-374-7782
Employees1,300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$216.82 million
Book Value$3.93 per share

Profitability

Net Income$-241,960,000.00
Net Margins-182.73%

Miscellaneous

Market Cap$6.38 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$48.39
+1.36 (+2.89 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InVitae (NYSE:NVTA) Frequently Asked Questions

How has InVitae's stock been impacted by Coronavirus (COVID-19)?

InVitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVTA shares have increased by 205.3% and is now trading at $48.39.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of InVitae?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae
.

When is InVitae's next earnings date?

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae
.

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.15. The medical research company had revenue of $46.20 million for the quarter, compared to the consensus estimate of $39.63 million. InVitae had a negative net margin of 182.73% and a negative return on equity of 77.82%. The company's revenue was down 14.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.54) EPS.
View InVitae's earnings history
.

What price target have analysts set for NVTA?

7 analysts have issued 12 month price objectives for InVitae's stock. Their forecasts range from $20.00 to $48.00. On average, they anticipate InVitae's stock price to reach $36.75 in the next twelve months. This suggests that the stock has a possible downside of 24.1%.
View analysts' price targets for InVitae
.

Who are some of InVitae's key competitors?

What other stocks do shareholders of InVitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

Who are InVitae's key executives?

InVitae's management team includes the following people:
  • Dr. Randal W. Scott, Exec. Chairman (Age 61)
  • Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
  • Mr. Lee Bendekgey, Sec. & COO (Age 61)
  • Ms. Laura D'Angelo, Head of Investor Relations

When did InVitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are InVitae's major shareholders?

InVitae's stock is owned by a variety of institutional and retail investors. Top institutional investors include Focused Wealth Management Inc (0.02%), RFG Advisory LLC (0.02%), Avitas Wealth Management LLC (0.01%), Carnegie Capital Asset Management LLC (0.01%), Spearhead Capital Advisors LLC (0.01%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae
.

Which institutional investors are selling InVitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Avitas Wealth Management LLC, and Focused Wealth Management Inc. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae
.

Which institutional investors are buying InVitae stock?

NVTA stock was bought by a variety of institutional investors in the last quarter, including Carnegie Capital Asset Management LLC, RFG Advisory LLC, Pacer Advisors Inc., Envestnet Asset Management Inc., CWM LLC, Creative Financial Designs Inc. ADV, Spearhead Capital Advisors LLC, and Flagship Harbor Advisors LLC.
View insider buying and selling activity for InVitae
.

How do I buy shares of InVitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InVitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $48.39.

How big of a company is InVitae?

InVitae has a market capitalization of $6.38 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

What is InVitae's official website?

The official website for InVitae is www.invitae.com.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]

This page was last updated on 10/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.